Summary                      

IPG6620 is an innovative, first-in-class, preclinical small-molecule antagonist of the LPAR5 receptor. It is being developed to address critical unmet medical needs in Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common and debilitating side effect of cancer treatment with severely limited treatment options. By targeting a novel pathway in neuropathic pain, IPG6620 represents a mechanistically distinct therapeutic strategy with the potential to both improve patient quality of life and boost the effectiveness of treatment.

Mechanism of Action

￭  For Neuropathic Pain (CIPN): LPAR5 is highly expressed in dorsal root ganglion (DRG) neurons and microglia. Chemotherapy-induced nerve injury leads to upregulation of LPAR5’s endogenous ligand, driving cellular activation and a sustained pro-inflammatory cascade. This signaling cascade disrupts normal DRG function and is a core driver of neuropathic pain. By blocking LPAR5, IPG6620 is designed to attenuate this neuro-inflammatory signaling pathway, thereby alleviating the symptoms of CIPN.

Key Differentiation

￭ Novel MoA: Directly targets neuroinflammatory signaling pathways (cAMP / PKA / CREB) at the cellular level, which offers a mechanism distinct from ion channel blockade, potentially providing efficacy in patients refractory to Nav1.8 inhibitors.

￭ Truly First-in-Class Target: LPAR5 represents a novel, untapped therapeutic target in this field, offering a mechanistically distinct approach from current CIPN treatments (e.g., duloxetine, gabapentin), which are largely repurposed agents with limited and inconsistent efficacy.

￭ Addressing a Major Unmet Medical Need: CIPN remains a pervasive clinical challenge with highly unsatisfactory treatment options. Clinical guidelines recommend only duloxetine as a first-line agent, and its utility is limited by adverse effects and incomplete symptom relief. IPG6620 may offer a more effective, better-tolerated therapeutic alternative.

￭ Broad Therapeutic Potential: Beyond CIPN, IPG6620's mechanism of action supports potential applications in other neuropathic pain conditions, such as diabetic peripheral neuropathy and postherpetic neuralgia, significantly expanding its therapeutic and market scope.

Current Development & Status

￭ IPG6620 is currently in the preclinical development stage. IND-enabling studies are actively progressing to support subsequent clinical trial initiation.